Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Anti-HIV therapy update

    Project Inform Perspective
    |June 1, 2002
    PubMed
    Summary
    This summary is machine-generated.

    The FDA approved tenofovir (Viread) for HIV treatment, offering a new option for patients. However, a limited access program for T-20 (enfuvirtide) is available to only 168 people initially.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same journal

    Everything antiretroviral: 5th IAS conference, Cape Town, South Africa.

    Project Inform perspective·2012
    Same journal

    Well implemented, President Obama's national HIV/AIDS strategy is precisely what is needed to further control HIV/AIDS.

    Project Inform perspective·2011
    Same journal

    Finding health care; preparing for the future.

    Project Inform perspective·2011
    Same journal

    Protecting people with HIV in the California budget.

    Project Inform perspective·2010
    Same journal

    Current drugs in clinical study.

    Project Inform perspective·2010
    Same journal

    HIV treatment information.

    Project Inform perspective·2010
    See all related articles

    Area of Science:

    • Virology
    • Pharmacology
    • Public Health

    Background:

    • Recent advancements in anti-HIV drug development have yielded both positive and negative outcomes.
    • The U.S. Food and Drug Administration (FDA) approved tenofovir (Viread) for treating Human Immunodeficiency Virus (HIV).
    • An expanded access program for the fusion inhibitor T-20 (enfuvirtide) has been announced.

    Discussion:

    • Tenofovir (Viread) presents a new therapeutic option for initial HIV treatment regimens and for salvage therapy.
    • The T-20 (enfuvirtide) expanded access program is currently limited in scope, initially serving only 168 patients in the United States.
    • The limited availability of T-20 (enfuvirtide) highlights ongoing challenges in scaling up access to novel HIV therapeutics.

    Key Insights:

    • FDA approval of tenofovir (Viread) expands treatment options for individuals with HIV.

    Related Experiment Videos

  • The restricted scale of the T-20 (enfuvirtide) access program underscores the need for broader availability of advanced HIV medications.
  • Balancing drug approval with accessible patient programs remains a critical aspect of HIV/AIDS management.

    • Outlook:

    • Future drug development efforts should focus on increasing the accessibility of promising HIV therapies.
    • Continued research and production scaling are essential to meet the demand for new anti-HIV drugs like T-20 (enfuvirtide).
    • The long-term impact of tenofovir (Viread) on HIV treatment paradigms and patient outcomes will be closely monitored.